CARDIO DIAGNOSTICS HOLDINGS (CDIO) Stock Price, Forecast & Analysis
NASDAQ:CDIO • US14159C2026
CDIO Key Statistics, Chart & Performance
The current stock price of CDIO is 1.29 USD. In the past month the price decreased by -29.12%. In the past year, price decreased by -93.58%.
CDIO Technical Analysis
CDIO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CDIO. No worries on liquidiy or solvency for CDIO as it has an excellent financial health rating, but there are worries on the profitability.
CDIO Financial Highlights
Over the last trailing twelve months CDIO reported a non-GAAP Earnings per Share(EPS) of -9.9. The EPS increased by 50% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -74.52% | ||
| ROE | -80.37% | ||
| Debt/Equity | 0 |
CDIO Forecast & Estimates
For the next year, analysts expect an EPS growth of 22.73% and a revenue growth 854.55% for CDIO
CDIO Ownership
CDIO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.67 | 402.079B | ||
| AMGN | AMGEN INC | 16.25 | 197.191B | ||
| GILD | GILEAD SCIENCES INC | 17.02 | 188.348B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.81 | 117.985B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.87 | 82.362B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.05 | 40.753B | ||
| INSM | INSMED INC | N/A | 31.174B | ||
| BIIB | BIOGEN INC | 12.85 | 28.692B | ||
| NTRA | NATERA INC | N/A | 28.683B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.16 | 20.502B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CDIO
Company Profile
Cardio Diagnostics Holdings, Inc. engages in the provision of medical diagnostic testing services. The company is headquartered in Chicago, Illinois and currently employs 13 full-time employees. The company went IPO on 2021-11-23. The firm develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.
Company Info
CARDIO DIAGNOSTICS HOLDINGS
311 W. Superior Street, Suite 444
Chicago ILLINOIS US
Employees: 13
Phone: 18552269991
CARDIO DIAGNOSTICS HOLDINGS / CDIO FAQ
What does CDIO do?
Cardio Diagnostics Holdings, Inc. engages in the provision of medical diagnostic testing services. The company is headquartered in Chicago, Illinois and currently employs 13 full-time employees. The company went IPO on 2021-11-23. The firm develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.
What is the current price of CDIO stock?
The current stock price of CDIO is 1.29 USD. The price decreased by -2.27% in the last trading session.
Does CARDIO DIAGNOSTICS HOLDINGS pay dividends?
CDIO does not pay a dividend.
What is the ChartMill technical and fundamental rating of CDIO stock?
CDIO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the market cap for CARDIO DIAGNOSTICS HOLDINGS?
CARDIO DIAGNOSTICS HOLDINGS (CDIO) has a market capitalization of 2.36M USD. This makes CDIO a Nano Cap stock.
What is the Short Interest ratio of CARDIO DIAGNOSTICS HOLDINGS (CDIO) stock?
The outstanding short interest for CARDIO DIAGNOSTICS HOLDINGS (CDIO) is 7.86% of its float.